 This study was designed to evaluate and compare the safety and tolerability of tenofovir disoproxil fumarate TDF, emtricitabine FTCTDF, and entecavir ETV in the treatment of hepatitis B patients with decompensated liver disease. Safety was assessed by evaluating adverse events AEs and laboratory abnormalities. Efficacy was assessed by evaluating reductions in Child-Pugh-Turcotte CPT and Model for End Stage Liver Disease MELD scores, reductions in hepatitis B virus HBV deoxyribonucleic acid DNA, changes in liver enzymes, development of drug-resistant mutations, and generation of antibody to virus. 